Last reviewed · How we verify
NCT02929654
Assessment of Blood Glucose Monitoring Devices With New Insight Features
NA trial testing OneTouch Verio® in Diabetes Mellitus in 267 participants. Completed in 22 June 2017.
22 June 2017
Quick facts
| Lead sponsor | LifeScan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | none |
| Primary purpose | other |
| Enrollment | 267 |
| Start date | 1 October 2016 |
| Primary completion | 22 June 2017 |
| Estimated completion | 22 June 2017 |
| Sites | 3 locations across United Kingdom |
Drugs / interventions tested
- OneTouch Verio®
- OneTouch Verio® Flex
- Subject's Own Blood Glucose Meter
Conditions studied
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
LifeScan
Who can join
Adults 18 to 75, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate whether novel insight features in new BGMs can improve glycemic control.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study).
Grady M, Katz LB, Levy BL. · · 2018 · cited 24× · PMID 29848106 · DOI 10.1177/1932296818775755
Verify or expand the search:
- PubMed search for NCT02929654
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
- NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
- NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting
Other LifeScan trials
Trials by the same sponsor.
- NCT05354297 — Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions · NA · unknown
- NCT03556605 — Tu Salud (Your Health) Randomized Control Study in Patients With Diabetes Using a Mobile App. · NA · unknown
- NCT03138174 — OneTouch Verio Flex System Accuracy Evaluation · completed
- NCT03189225 — Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference and YSI · NA · completed
- NCT02374879 — User Performance and System Accuracy Evaluations Using Glucose Adjustment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02929654 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LifeScan
- Last refreshed: 15 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02929654.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing